111 related articles for article (PubMed ID: 24565208)
1. Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections.
Castellini P; Montironi MA; Zizzi A; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Paone N; Montironi R
Hum Pathol; 2014 Apr; 45(4):745-52. PubMed ID: 24565208
[TBL] [Abstract][Full Text] [Related]
2. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
Barbisan F; Santinelli A; Mazzucchelli R; Lopez-Beltran A; Cheng L; Scarpelli M; van der Kwast T; Montironi R
Cancer; 2008 Feb; 112(3):636-44. PubMed ID: 18072261
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential.
Barbisan F; Mazzucchelli R; Santinelli A; Stramazzotti D; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Int J Immunopathol Pharmacol; 2008; 21(3):615-23. PubMed ID: 18831929
[TBL] [Abstract][Full Text] [Related]
4. Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.
Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Bartels H; Bartels PH; Alberts DS; Montironi R
Int J Immunopathol Pharmacol; 2011; 24(2):489-97. PubMed ID: 21658323
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma.
Zizzi A; Montironi MA; Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Paone N; Castellini P; Montironi R
Diagn Pathol; 2013 Jul; 8():111. PubMed ID: 23819605
[TBL] [Abstract][Full Text] [Related]
7. Chromatin phenotype karyometry can predict recurrence in papillary urothelial neoplasms of low malignant potential.
Montironi R; Scarpelli M; Lopez-Beltran A; Mazzucchelli R; Alberts D; Ranger-Moore J; Bartels HG; Hamilton PW; Einspahr J; Bartels PH
Cell Oncol; 2007; 29(1):47-58. PubMed ID: 17429141
[TBL] [Abstract][Full Text] [Related]
8. Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP).
Jones TD; Cheng L
Histopathology; 2020 Oct; 77(4):525-535. PubMed ID: 32562556
[TBL] [Abstract][Full Text] [Related]
9. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
10. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome.
Campbell PA; Conrad RJ; Campbell CM; Nicol DL; MacTaggart P
BJU Int; 2004 Jun; 93(9):1228-31. PubMed ID: 15180612
[TBL] [Abstract][Full Text] [Related]
11. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder.
Cheng L; MacLennan GT; Zhang S; Wang M; Pan CX; Koch MO
Cancer; 2004 Jul; 101(1):183-8. PubMed ID: 15222005
[TBL] [Abstract][Full Text] [Related]
12. Bladder papillary urothelial neoplasm of low malignant potential in Chinese: a clinical and pathological analysis.
Zhang XK; Wang YY; Chen JW; Qin T
Int J Clin Exp Pathol; 2015; 8(5):5549-55. PubMed ID: 26191263
[TBL] [Abstract][Full Text] [Related]
13. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts.
Jones TD; Cheng L
J Urol; 2006 Jun; 175(6):1995-2003. PubMed ID: 16697785
[TBL] [Abstract][Full Text] [Related]
14. [New WHO classification of urothelial carcinoma of the urinary bladder].
Helpap B
Verh Dtsch Ges Pathol; 2002; 86():57-66. PubMed ID: 12647352
[TBL] [Abstract][Full Text] [Related]
15. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?
Garbar C; Mascaux C
Anal Quant Cytol Histol; 2011 Oct; 33(5):277-82. PubMed ID: 22611755
[TBL] [Abstract][Full Text] [Related]
16. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis.
Kaymaz E; Ozer E; Unverdi H; Hucumenoglu S
Indian J Pathol Microbiol; 2017; 60(4):510-514. PubMed ID: 29323063
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
19. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification.
Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI
J Urol; 2005 Nov; 174(5):1976-80. PubMed ID: 16217372
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases.
Pan CC; Chang YH; Chen KK; Yu HJ; Sun CH; Ho DM
Am J Clin Pathol; 2010 May; 133(5):788-95. PubMed ID: 20395527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
